Literature DB >> 23911231

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

Joseph P Kitzmiller1, Philip F Binkley, Saurabh R Pandey, Adam M Suhy, Damiano Baldassarre, Katherine Hartmann.   

Abstract

Indicated for treating hyperlipidemias and for the prevention of cardiovascular disease (CVD), statins rank among the most commonly prescribed drug classes. While statins are considered to be highly effective in preventing atherosclerotic events, a substantial portion of treated patients still progress to overt CVD. Genetic factors are thought to contribute substantially to treatment outcome. Several candidate genes have been associated with statin dose requirements and treatment outcomes, but a clinically relevant pharmacogenomics test to guide statin therapy has not yet emerged. Here we define basic pharmacogenomics terminology, present strong candidate genes (CETP, HMGCR, SLCO1B1, ABCB1, and CYP3A4/5), and discuss the challenges in developing much-needed statin pharmacogenomics biomarkers for predicting treatment outcomes.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23911231      PMCID： PMC4039562     

Source DB:  PubMed          Journal:  Discov Med        ISSN： 1539-6509            Impact factor:   2.970


  34 in total

1.  Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.

Authors:  Laure Elens; Matthijs L Becker; Vincent Haufroid; Albert Hofman; Loes E Visser; André G Uitterlinden; Bruno Ch Stricker; Ron H N van Schaik
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

2.  Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

Authors:  S M Boekholdt; F M Sacks; J W Jukema; J Shepherd; D J Freeman; A D McMahon; F Cambien; V Nicaud; G J de Grooth; P J Talmud; S E Humphries; G J Miller; G Eiriksdottir; V Gudnason; H Kauma; S Kakko; M J Savolainen; M Arca; A Montali; S Liu; H J Lanz; A H Zwinderman; J A Kuivenhoven; J J P Kastelein
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

3.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

Authors:  Danxin Wang; Andrew D Johnson; Audrey C Papp; Deanna L Kroetz; Wolfgang Sadée
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

4.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Jessie L Werner; Lisa Christopher-Stine; Sharon R Ghazarian; Katherine S Pak; Jordan E Kus; Natalie R Daya; Thomas E Lloyd; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2012-12

5.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.

Authors:  J A Kuivenhoven; J W Jukema; A H Zwinderman; P de Knijff; R McPherson; A V Bruschke; K I Lie; J J Kastelein
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

6.  Pharmacogenetic study of statin therapy and cholesterol reduction.

Authors:  Daniel I Chasman; David Posada; Lakshman Subrahmanyan; Nancy R Cook; Vincent P Stanton; Paul M Ridker
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

7.  Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

Authors:  Kari T Kivistö; Mikko Niemi; Elke Schaeffeler; Kaisu Pitkälä; Reijo Tilvis; Martin F Fromm; Matthias Schwab; Michel Eichelbaum; Timo Strandberg
Journal:  Pharmacogenetics       Date:  2004-08

8.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

Authors:  Mikko Niemi; Elke Schaeffeler; Thomas Lang; Martin F Fromm; Mikko Neuvonen; Carl Kyrklund; Janne T Backman; Reinhold Kerb; Matthias Schwab; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö
Journal:  Pharmacogenetics       Date:  2004-07

9.  Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity.

Authors:  D J Freeman; B A Griffin; A P Holmes; G M Lindsay; D Gaffney; C J Packard; J Shepherd
Journal:  Arterioscler Thromb       Date:  1994-03

10.  Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.

Authors:  Audrey C Papp; Julia K Pinsonneault; Danxin Wang; Leslie C Newman; Yan Gong; Julie A Johnson; Carl J Pepine; Meena Kumari; Aroon D Hingorani; Philippa J Talmud; Sonia Shah; Steve E Humphries; Wolfgang Sadee
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240
View more
  9 in total

1.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

2.  Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.

Authors:  Elbatool G Elalem; Musharraf Jelani; Alaa Khedr; Aftab Ahmad; Tareef Y Alaama; Mohamed Nabeel Alaama; Huda M Al-Kreathy; Zoheir A Damanhouri
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

3.  ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis.

Authors:  Jia Su; Hongyu Xu; Jun Yang; Qinglin Yu; Shujun Yang; Jianjiang Zhang; Qi Yao; Yunyun Zhu; Yuan Luo; Lindan Ji; Yibo Zheng; Jingbo Yu
Journal:  Lipids Health Dis       Date:  2015-10-06       Impact factor: 3.876

Review 4.  Lipids, blood pressure and kidney update 2015.

Authors:  Maciej Banach; Wilbert S Aronow; Maria-Corina Serban; Jacek Rysz; Luminita Voroneanu; Adrian Covic
Journal:  Lipids Health Dis       Date:  2015-12-30       Impact factor: 3.876

5.  Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.

Authors:  Dominic Mitchell; Jason R Guertin; Ange Christelle Iliza; Fiorella Fanton-Aita; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

6.  Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.

Authors:  Ralph Kwame Akyea; Joe Kai; Nadeem Qureshi; Barbara Iyen; Stephen F Weng
Journal:  Heart       Date:  2019-04-15       Impact factor: 5.994

7.  A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy.

Authors:  Saowalak Turongkaravee; Jiraphun Jittikoon; Thitiya Lukkunaprasit; Sermsiri Sangroongruangsri; Usa Chaikledkaew; Ammarin Thakkinstian
Journal:  Pharmacogenomics J       Date:  2021-02-19       Impact factor: 3.550

8.  Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population.

Authors:  Filipp Filippovich Vasilyev; Diana Aleksandrovna Danilova; Vladimir Sergeevich Kaimonov; Yana Valerievna Chertovskih; Nadezda Romanovna Maksimova
Journal:  Res Pharm Sci       Date:  2016 May-Jun

9.  KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.

Authors:  Cristina Ruiz-Iruela; Ariadna Padró-Miquel; Xavier Pintó-Sala; Neus Baena-Díez; Assumpta Caixàs-Pedragós; Roser Güell-Miró; Rosa Navarro-Badal; Xavier Jusmet-Miguel; Pilar Calmarza; José Luis Puzo-Foncilla; Pedro Alía-Ramos; Beatriz Candás-Estébanez
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.